|Page (1) of 1 - 12/12/12||email article||print page|
Harvard Bioscience (HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., filed a registration statement with the SEC for an initial public offering, or IPO, of Harvard Apparatus Regenerative Technology's common stock. Following the IPO, Harvard Apparatus Regenerative Technology will own Harvard Bioscience's regenerative medicine device business, which develops life-saving medical devices in the field of regenerative medicine, including devices to be used by physicians for growing organs outside the body for transplant.
|Harvard Bioscience Announces Filing of IPO Registration Statement for Harvard Apparatus Regenerative Technology|
Source:GrabNetworks (c). All Rights Reserved